​

Smith & Nephew (SNN) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

SNN Stock Forecast

Smith & Nephew (SNN) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $36.75, with a high of $37.50 and a low of $36.00. This represents a 0.57% increase from the last price of $36.54.

$20 $24 $28 $32 $36 $40 High: $37.5 Avg: $36.75 Low: $36 Last Closed Price: $36.54

SNN Stock Rating

Smith & Nephew stock's rating consensus is Hold, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (27.27%), 15 Hold (68.18%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Hold
Total 22 1 15 6 0 Strong Sell Sell Hold Buy Strong Buy

SNN Price Target Upside V Benchmarks

TypeNameUpside
StockSmith & Nephew0.57%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks20.18%

Price Target Trends

1M3M12M
# Anlaysts123
Avg Price Target$37.50$36.75$33.50
Last Closing Price$36.54$36.54$36.54
Upside/Downside2.63%0.57%-8.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-23--5
Sep, 25-23--5
Aug, 25112--4
Jul, 25112--4
Jun, 25112--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2025Bernstein$37.50$35.216.50%2.63%
Aug 18, 2025Caitlin CroninCanaccord Genuity$36.00$36.54-1.48%-1.48%
Nov 04, 2024Kyle RoseCanaccord Genuity$27.00$25.286.80%-26.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2025RBC CapitalOutperformOutperformhold
Oct 14, 2025BernsteinMarket Performdowngrade
Mar 03, 2025Deutsche BankHoldHoldhold
Nov 04, 2024Canaccord GenuityHoldHoldhold
Oct 14, 2024RBC CapitalOutperformOutperformhold
Aug 02, 2024BarclaysEqual-WeightEqual-Weighthold
Jul 24, 2024Deutsche BankBuyinitialise
Jun 05, 2024UBSNeutralBuyupgrade
May 22, 2024LiberumHolddowngrade
Oct 04, 2022BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.51$0.60$0.26$0.60-----
Avg Forecast$1.26$1.65$1.55$1.64$1.66$1.94$2.16$2.33$2.57
High Forecast$1.28$1.68$1.59$1.85$1.67$2.01$2.21$2.34$2.59
Low Forecast$1.25$1.64$1.54$1.48$1.64$1.89$2.09$2.31$2.55
Surprise %-59.52%-63.64%-83.23%-63.41%-----

Revenue Forecast

$5B $5B $6B $6B $7B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.56B$5.21B$5.21B$5.55B-----
Avg Forecast$4.61B$5.22B$5.20B$5.55B$5.78B$6.04B$6.36B$6.69B$7.14B
High Forecast$4.67B$5.28B$5.29B$5.57B$5.78B$6.06B$6.37B$6.72B$7.17B
Low Forecast$4.58B$5.19B$5.17B$5.51B$5.73B$6.03B$6.35B$6.64B$7.09B
Surprise %-1.19%-0.18%0.29%0.05%-----

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$448.00M$524.00M$223.00M$263.00M-----
Avg Forecast$894.21M$983.63M$1.08B$1.19B$724.19M$846.78M$944.73M$1.02B$1.12B
High Forecast$1.07B$1.18B$1.30B$1.43B$728.48M$876.42M$965.91M$1.02B$1.13B
Low Forecast$715.37M$786.91M$865.60M$952.16M$715.62M$825.61M$915.07M$1.01B$1.11B
Surprise %-49.90%-46.73%-79.39%-77.90%-----

SNN Forecast FAQ

Is Smith & Nephew stock a buy?

Smith & Nephew stock has a consensus rating of Hold, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 15 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Smith & Nephew is a neutral investment for most analysts.

What is Smith & Nephew's price target?

Smith & Nephew's price target, set by 22 Wall Street analysts, averages $36.75 over the next 12 months. The price target range spans from $36 at the low end to $37.5 at the high end, suggesting a potential 0.57% change from the previous closing price of $36.54.

How does Smith & Nephew stock forecast compare to its benchmarks?

Smith & Nephew's stock forecast shows a 0.57% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (20.18%).

What is the breakdown of analyst ratings for Smith & Nephew over the past three months?

  • October 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Smith & Nephew’s EPS forecast?

Smith & Nephew's average annual EPS forecast for its fiscal year ending in December 2024 is $1.66, marking a 176.67% increase from the reported $0.6 in 2023. Estimates for the following years are $1.94 in 2025, $2.16 in 2026, $2.33 in 2027, and $2.57 in 2028.

What is Smith & Nephew’s revenue forecast?

Smith & Nephew's average annual revenue forecast for its fiscal year ending in December 2024 is $5.78B, reflecting a 4.07% increase from the reported $5.55B in 2023. The forecast for 2025 is $6.04B, followed by $6.36B for 2026, $6.69B for 2027, and $7.14B for 2028.

What is Smith & Nephew’s net income forecast?

Smith & Nephew's net income forecast for the fiscal year ending in December 2024 stands at $724.19M, representing an 175.36% increase from the reported $263M in 2023. Projections indicate $846.78M in 2025, $944.73M in 2026, $1.02B in 2027, and $1.12B in 2028.